Organogenesis Holdings Inc. (ORGO) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates strong financial performance with a 10% revenue increase and a 25% rise in net income. Gross margins also improved by 2%, and cash flow from operations increased by 15%. These positive financial metrics, coupled with optimistic guidance for revenue growth and margin improvement, suggest a positive stock price movement. However, the lack of discussion on strategic initiatives and risks tempers the outlook slightly, leading to a 'Positive' sentiment rather than 'Strong positive.'
Key Financial Performance
Revenue $120 million, a 10% increase year-over-year, driven by strong demand for our advanced wound care products.
Gross Margin 65%, a 2% improvement year-over-year, attributed to operational efficiencies and cost management initiatives.
Net Income $15 million, a 25% increase year-over-year, due to higher revenue and improved gross margins.
Operating Expenses $50 million, a 5% increase year-over-year, primarily due to investments in sales and marketing.
Cash Flow from Operations $20 million, a 15% increase year-over-year, reflecting improved profitability and working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BTIG LLC
CEO Chair
Chair Francisco
Division PM
Francisco Chief
Gary Gillheeney
Gillheeney President
Iseult McMahon
LLC Research
McMahon BTIG
Officer Iseult
PM EDT
President CEO
Research Division
ORGO Transcript
Organogenesis Holdings Inc. (ORGO) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call indicates strong financial performance with a 10% revenue increase and a 25% rise in net income. Gross margins also improved by 2%, and cash flow from operations increased by 15%. These positive financial metrics, coupled with optimistic guidance for revenue growth and margin improvement, suggest a positive stock price movement. However, the lack of discussion on strategic initiatives and risks tempers the outlook slightly, leading to a 'Positive' sentiment rather than 'Strong positive.'
Organogenesis Holdings Inc. (ORGO) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call summary indicates strong financial performance with a 10% revenue increase, improved gross margins, and a 25% rise in net income. Strategic initiatives focus on product innovation and market expansion, supported by favorable market trends. The positive outlook for revenue and margin improvements in 2026 further boosts sentiment. Despite potential regulatory risks, the overall tone is optimistic, suggesting a positive stock price movement over the next two weeks.
Organogenesis Holdings Inc. (ORGO) Q3 2025 Earnings Call Transcript
Unknown11-7
The earnings call presents a mixed picture: strong revenue growth and improved net income are positive, but increased operating expenses and cash position decline are concerning. The Q&A reveals uncertainties in FDA approval timelines and unclear management responses on financial guidance, which may dampen investor confidence. The company's guidance is cautious, with potential for modest revenue growth. Overall, the sentiment is balanced, leading to a neutral prediction for stock movement.
Organogenesis Holdings Inc. (ORGO) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call reveals several negative aspects: declining net product revenue, a significant EBITDA loss, and reduced cash reserves. Despite some positive notes in surgical product revenue and potential CMS reimbursement changes, the company's heavy dependence on regulatory approvals and operational risks in new facilities pose significant challenges. The Q&A section revealed reduced guidance and aggressive market behavior, further contributing to a negative sentiment. Overall, these factors suggest a negative stock price movement in the short term.
ORGO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
